Pharmaceutical

Earth Science Tech, Inc., Reports Record Fiscal Q1 2023 Financial Results

“Strategy is important, execution is everything.” Miami, FL, July 28, 2023 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST)…

11 months ago

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the…

11 months ago

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Company announces participation in BTIG Virtual Biotechnology ConferenceNEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a…

11 months ago

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meetingSAN DIEGO, July 28, 2023…

11 months ago

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…

11 months ago

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and…

11 months ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical…

11 months ago

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”),  a clinical…

11 months ago

Lexicon Elects Diane E. Sullivan to Board of Directors

Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of DirectorsTHE WOODLANDS, Texas, July…

11 months ago

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development…

11 months ago